Patents Assigned to Du Pont Merck Pharmaceutical
  • (Amidomethyl)nitrogen heterocyclic analgesics
    Patent number: 5254569
    Abstract: This invention relates to (amidomethyl)nitrogen heterocyclic and pyrrolidine compounds, pharmaceutical compositions containing them, methods of using such compounds and processes for making such compounds.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: October 19, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Robert S. Cheeseman, Hollis S. Kezar, III, Richard M. Scribner
  • Clipsin, a chymotrypsin-like protease and method of using same
    Patent number: 5252463
    Abstract: A novel M.sub.r 25,000 chymotrypsin-like protease, termed clipsin, which binds to a-1-AChy in a sodium dodecyl sulfate-resistant manner, preferentially degrades .beta.-APP, and shows high activity for a period of a few days in neonatal rat brain is disclosed. Preparation of clipsin in a form that allows clipsin proteolytic activity to be measured under conditions substantially free of the activity other cellular non-clipsin proteases is also disclosed. Further disclosed is a method of identifying potential therapeutic agents for the treatment of selected neuropathologies such as Down's syndrome and Alzheimer's disease by measuring or inhibition of clipsin.
    Type: Grant
    Filed: June 22, 1990
    Date of Patent: October 12, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Robert B. Nelson, Robert G. Siman
  • Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
    Patent number: 5252586
    Abstract: Novel unsaturated ether derivatives of alkyl piperidine and pyrrolidine compounds, pharmaceutical compositions containing them, methods of preparation and methods of using these compounds as antipsychotic agents are disclosed.
    Type: Grant
    Filed: September 28, 1990
    Date of Patent: October 12, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Thomas E. Christos, Sang W. Tam
  • Blood cryopreservation container
    Patent number: 5250044
    Abstract: This invention relates to bags for the cryopreservation of mammalian cells and particularly for the long-term freezing of red blood cell. This invention also relates to methods of manufacturing such bags.
    Type: Grant
    Filed: February 6, 1990
    Date of Patent: October 5, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Joseph D. Irr, John D. Walker
  • Antipsychotic 1-cycloalkylpiperidines
    Patent number: 5243048
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: September 7, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Diagnostic assay for alzheimer's disease
    Patent number: 5234814
    Abstract: A method to assist in the diagnosis of Alzheimer's disease comprising detecting, in bodily fluids, two APP-related proteins, in soluble form, said proteins have an apparent molecular size of about 130 kDa and about 35 kDa, and each of said proteins shares at least one epitope with the C-terminus of APP corresponding substantially to amino acids 676-695 of APP as shown in FIG. 1.
    Type: Grant
    Filed: June 1, 1989
    Date of Patent: August 10, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: John P. Card, Leonard G. Davis, Robert G. Siman
  • Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
    Patent number: 5231099
    Abstract: The invention relates to a method of treating psychosis in a mammal which comprises administering to the mammal an effective amount of a dopamine receptor antagonist antipsychotic and a sigma receptor antagonist having greater affinity for sigma receptors than for dopamine receptors, in an amount effective to selectively enhance the antipsychotic effects of the dopamine receptor antagonist relative to the adverse side effects of the dopamine receptor antagonist.
    Type: Grant
    Filed: April 15, 1991
    Date of Patent: July 27, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Leonard Cook
  • Monoclonal antibodies to tissue plasminogen activator (T-PA) which prolong its functional half-life
    Patent number: 5225540
    Abstract: High-affinity murine monoclonal antibodies to t-PA were prepared which prolong the in vivo functional half-life of t-PA without decreasing its plasminogen-activator activity.
    Type: Grant
    Filed: April 26, 1988
    Date of Patent: July 6, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Thomas M. Reilly, Andrew T. Chiu, Robert M. Knabb
  • 5H-(1,2)benzisothiazolo[2,3-a]quinoline-5-ones and analogs as antiinflammatory agents
    Patent number: 5225418
    Abstract: The present invention relates to novel 5H-[1,2]benzisothiazolo[2,3-a]quinoline-5-ones, processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods of using these compounds for the treatment of inflammatory disorders.
    Type: Grant
    Filed: December 17, 1991
    Date of Patent: July 6, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: William H. Miller
  • Heterocyclic steroid compounds
    Patent number: 5219879
    Abstract: The present invention relates to novel substituted 15-oxa-, 15-thia-, and 15-aza- dihydrolanosterols, to pharmaceutical compositions containing such compounds, and to methods of using these compounds to suppress the activity of 3-hydroxy-3- methylglutaryl coenzyme A reductase (HMGR), an enzyme which is important in cholesterol biosynthesis. The overall effect of these heterocyclic lanosterol analogs is to decrease cholesterol formation, thereby resulting in lower serum cholesterol levels in mammals, and impaired ergosterol synthesis in fungi.
    Type: Grant
    Filed: March 1, 1991
    Date of Patent: June 15, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Soo S. Ko, James M. Trzaskos
  • (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
    Patent number: 5217983
    Abstract: (Indol-1'-ylmethyl)-, (Indazol-1'-ylmethyl)-, (Benzimidazol-1'-ylmethyl)-, and (Benzotriazol-1'-ylmethyl)- phenylacetaldehydes as Topical Antiinflammatories.
    Type: Grant
    Filed: March 27, 1992
    Date of Patent: June 8, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Joseph J. Petraitis
  • Hydroisoindolines and hydroisoquinolines as psychotropic
    Patent number: 5216018
    Abstract: There are provided nitrogen-containing bicyclic compounds which are useful in the treatment of physiological or drug induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: June 1, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Engelbert Ciganek
  • Bis-naphthalimides containing amide and thioamide linkers as anticancer agents
    Patent number: 5206250
    Abstract: There are provided novel bis-naphthalimide compounds useful as antitumor agents, pharmaceutical compositions containing them and processes for preparing such compounds.
    Type: Grant
    Filed: March 27, 1991
    Date of Patent: April 27, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Jung-Hui Sun
  • Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
    Patent number: 5206249
    Abstract: This invention relates to bis-naphthalimides, including 2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis[5-nitro-1H-be nz[de]isoquinoline-1,3(2H)-dione] and 2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis[5-nitro-1H-be nz[de]isoquinoline-1,3(2H)-dione], processes for their preparation, pharmaceutical compositions containing them, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: April 27, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Jung-Hui Sun
  • Treatment of organ transplantation rejection
    Patent number: 5204329
    Abstract: 4-Quinoline-carboxylic acid derivatives, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinoline carboxylic acid, in combination with other immunosuppressive agents are useful for the treatment and/or prevention of transplantation rejection, graft vs. host disease, autoimmune diseases, and chronic inflammatory disease.
    Type: Grant
    Filed: June 11, 1990
    Date of Patent: April 20, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Neil R. Ackerman, Bruce D. Jaffee
  • Process for the preparation of moricizine hydrochloride
    Patent number: 5202435
    Abstract: Processes are provided for preparing crystalline moricizine hydrochloride from moricizine using hydrochloric acid, wherein the crystalline moricizine hydrochloride so obtained is substantially free of occluded water.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: April 13, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Gary O. Page
  • Etanidazole injectable solution
    Patent number: 5192784
    Abstract: Physically and chemically stable pharmaceutical compositions useful for administering etanidazole by injection are described. These compositions are essentially aqueous solutions having a pH less than or equal to 5.5, and containing etanidazole, a buffer system, and a tonicity-adjusting agent, and they are optionally stabilized by the addition of a stabilizing agent or by autoclaving.
    Type: Grant
    Filed: June 26, 1992
    Date of Patent: March 9, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Surendra M. Bahal, Kenneth S. Field, Michael B. Maurin
  • 3-phenyl-5,6-dihydrobenziciacridine-7-carboxylic acids and related compounds as immunosuppressive agents
    Patent number: 5190753
    Abstract: Dihydrobenz[c]acridine carboxylic acid derivatives are provided which are useful for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, psoriasis and chronic inflammatory diseases.
    Type: Grant
    Filed: June 5, 1992
    Date of Patent: March 2, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Carl H. Behrens, Bruce D. Jaffee
  • Peptide boronic acid inhibitors of trypsin-like proteases
    Patent number: 5187157
    Abstract: Peptides comprising C-terminal boronic acid derivatives of lysine, ornithine, and arginine, homoarginine and corresponding isothiouronium analogs thereof, are reversible inhibitors of trypsin-like serine proteases such as thrombin, plasma kallikrein and plasmin.
    Type: Grant
    Filed: April 6, 1988
    Date of Patent: February 16, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Charles A. Kettner, Ashokkumar B. Shenvi
  • Polycyclic ketones and preparative methods therefor
    Patent number: 5185447
    Abstract: Ketones having formulas (1)-(3) are provided by improved methods which involve the treatment of compounds having formulas (9)-(11) with aqueous base. ##STR1## wherein R.sub.x is NO.sub.2.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: February 9, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Edward C. Crapps